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Abstract
Background: Astrocyte elevated gene-1 (AEG-1) was originally characterized as a HIV-1-inducible
gene in primary human fetal astrocyte. Recent studies highlight a potential role of AEG-1  in
promoting tumor progression and metastasis. The aim of this study was to investigate if AEG-1
serves as a potential therapeutic target of human neuroblastoma.
Methods: We employed RNA interference to reduce AEG-1 expression in human neuroblastoma
cell lines and analyzed their phenotypic changes.
Results: We found that the knockdown of AEG-1  expression in human neuroblastoma cells
significantly inhibited cell proliferation and apoptosis. The specific downregulation induced cell
arrest in the G0/G1 phase of cell cycle. In the present study, we also observed a significant
enhancement of chemo-sensitivity to cisplatin and doxorubicin by knockdown of AEG-1.
Conclusion: Our study suggests that overexpressed AEG-1 enhance the tumorogenic properties
of neuroblastoma cells. The inhibition of AEG-1 expression could be a new adjuvant therapy for
neuroblastoma.
Background
Neuroblastoma is the most common solid tumor of
infancy. It is thought to arise from the anomalous arrest of
multi-potential embryonal cells of neural crest origin dur-
ing differentiation. The disordered differentiation contrib-
utes to the pathogenesis of the disease [1]. Prognosis of
neuroblastoma is in part related to tumor stage, the pres-
ence or absence of N-myc amplification, nuclear ploidy
and the age of onset [2-4]. Advanced neuroblastoma in
children over 1 year old has a very poor prognosis and is
resistant to standard chemotherapy. Although complete
or partial remissions are achieved in 74% of these chil-
dren with multi-agent high-dose therapy, long-term survi-
vors represent only 15–20% of relapsed patients [5,6].
Relapse and metastasis are the dominated negative factors
for survival. New approaches to inhibit aggressiveness and
increase chemo-sensitivity of neuroblastoma to antican-
cer agents are required.
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Astrocyte elevated gene-1 (AEG-1) was originally character-
ized as a human immunodeficiency virus (HIV)-1-induci-
ble gene in primary human fetal astrocyte [7,8], which is
a downstream target molecule of Ha-ras and c-myc medi-
ating their tumor promoting effects [9]. AEG-1 is ubiqui-
tously expressed in numerous cell types, elevated levels
have also been observed in some solid tumors including
those of breast, brain and prostate [9,10]. Intriguingly,
AEG-1 expression is elevated in diverse neoplastic condi-
tions, it cooperates with Ha-ras to promote transforma-
tion, and its overexpression in Hela cells induces
increased anchorage-independent growth and invasive-
ness and increase expression of adhesion molecules by
activating the NF-κB pathway [11]. However, such studies
are lacking in neuroblastoma.
Recently, we found that AEG-1 is also frequently overex-
pressed in neuroblastoma (submitted). In patients with
advanced neuroblastoma, poor clinical outcome were
observed related to AEG-1  overexpression, highlight a
potential role of AEG-1 in promoting tumor progression
and metastasis of neuroblastoma.
In the present study, we hypothesize that overexpressed
AEG-1  enhances tumorogenic properties of neuroblast-
oma cells in the same manner as observed in cultured
HeLa cells [11]. The inhibition of AEG-1 expression could
be a new adjuvant therapy for neuroblastoma.
Methods
Cell lines and culture
Human neuroblastoma cell lines M17 and SK-N-SH (Chi-
nese Type Culture Collection, Beijing, China) were main-
tained in Dulbecco's modified Eagle's medium (DMEM,
Invitrogen, Carlsbad, CA, USA) supplemented with 10%
heat-inactivated fetal bovine serum (FBS, Gibco, AUS) at
37°C in an atmosphere of 5% CO2 with humidity.
AEG-1-siRNA transfection
Knockdown of AEG-1  expression was achieved using
transfection of AEG-1-siRNA. AEG-1-siRNA1 and AEG-1-
siRNA2 targeting nucleotides 971–991 and 1355–1375 of
human AEG-1 mRNA sequence (GenBank Accession No.
NM_178812.3) were synthesized by Genepharma
(Shanghai, China) as shown in Table 1 and annealed to
form siRNA duplexes according to manufacturer's instruc-
tions. Non-targeting siRNA was used to control for non-
specific effects. Cells were transfected 24 hours under
standard culture conditions with 100 nM siRNA duplexes
using Lipofectamine™ 2000 (Invitrogen, Carlsbad, CA)
following manufacturer's protocols.
Real-time RT-PCR
Fourty-eight hours after transfection, cells were harvested
in TRIzol Reagent (Invitrogen) and total RNA was isolated
following the manufacturer's instructions. The first strand
cDNA was synthesized according to the manufacturer's
instructions (TaKaRa RT kit, Dalian, China). Quantitative
determination of AEG-1  transcript concentrations was
performed by real-time RT-PCR with GAPDH as an inter-
nal control. Primers for AEG-1 (sense 5' GGC AAT TGG
GTA GAC GAA GA 3'; antisense 5' CCT GTT TTG GAC
GGG TTT TA 3') and GAPDH (sense 5' GAG TCA ACG
GAT TTG GTC GT 3'; antisense 5' TTG ATT TTG GAG GGA
TCT CG 3') synthesized by Sangon (Shanghai, China) and
were used to measure gene expression. Amplification reac-
tion assays were set up triplicate for each sample using the
SYBR Green system (TaKaRa, Dalian, China). In order to
quantify the gene expression changes, the  Ct method was
used to calculate the relative fold-changes normalized
against GAPDH.
Western blot analysis
After 48 hours of transfection, cells and supernatant of
each group would be collected. Proteins were extracted
after break-down of cells by SDS boiling method. Proteins
were quantified by Bradford method. 50 μg of protein
underwent SDS-PAGE and was transferred to PVDF mem-
brane afterward. It was then sealed at room temperature
for 2 hours. The primary antibodies, rabbit anti-human
AEG-1 antibody (Invitrogen, Carlsbad, CA), was added at
a ratio of 1:1000, and incubated overnight at 4°C. The
membrane was washed with PBS. Then, the secondary
antibody, mouse anti-rabbit IgG/HRP antibodies (Amer-
sham Biosciences), was added at a ratio of 1:5000, and
incubated at room temperature for 2 hours. The mem-
brane was washed three times and reacted with chemilu-
minescent agent for 5 minutes. It was then ECL tabletting,
exposed, and displayed. The amount of each protein sam-
ple was controlled by β-actin.
Cell proliferation assay
M17 and SK-N-SH cells were transfected in 6-well plate.
24 hours late, the transfected cells were trypsinized and
plated in 96-well plates with 1.0 × 103 cells in 100 μl of the
medium and allowed to attach for 24 h, then 10 μl of MTT
(5 mg/ml in PBS) was added for 4 h incubation at 37°C
after 4, 24, 48, 72 h, respectively. Subsequently the forma-
zan crystals were solubilized with 100 μl of 10% sodium
Table 1: Targeted AEG-1 sequences and the control siRNA were 
chemically synthesized by Genepharma (Shanghai, China).
Name Senquences
AEG-1siRNA 1 s: 5'-GACACUGGAGAUGCUAAUAUU-3'
as: 5'-UAUUAGCAUCUCCAGUGUCUU-3'
AEG-1siRNA 2 s: 5'-GGUGAAGAUAACUCUACUGUU-3'
as: 5'-CAGUAGAGUUAUCUUCACCUU-3'
Control siRNA s: 5'-UUCUCCGAACGUGUCACGUTT-3'
as: 5'-ACGUGACACGUUCGGAGAATT-3'Journal of Experimental & Clinical Cancer Research 2009, 28:19 http://www.jeccr.com/content/28/1/19
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dodecyl sulfate (SDS) in 0.01 M HCl for 24 h. The absorb-
ance was measured using a Microplate Reader (Bio-rad
680, Bio-rad, USA) with a test wavelength of 570 nm and
a reference wavelength of 630 nm and all experiments
were performed in triplicate. The cell proliferation curve
was plotted using the absorbance at each time point.
Colonogenic assay
The number of colonies was determined as described pre-
viously [12]. Briefly, following transfection for 48 h, cells
were trypsinized, counted, and seeded for the colony
forming assay in 60 mm dishes at 200 cells per dish. After
incubation for 14 days, colonies were stained with crystal
violet and the numbers of positive cells counted. Colonies
containing more than 50 cells were scored, and triplicates
containing 10–150 colonies/dish were counted in each
treatment.
Flow cytometry analysis
Detection of apoptosis and cell cycle by flow cytometry
was performed using the Annexin V-FITC kit (Becton
Dickinson, CA, USA). The transfected cells were harvested
with trypsinization, fixed with cold 70% ethanol at 4°C
for 24 hours. The staining was performed according to the
producer's manual. Flow cytometry (Becton Dickinson,
CA, USA) was performed immediately.
Cell viability assay
Cell viability assay was performed as described previously
[12]. Cells were seeded in 96-well plates (Corning, NY,
USA). After overnight culture, they were exposed to vari-
ous concentrations of cisplatin or doxorubicin for 48 h in
a CO2 incubator. MTT assay as described above was used
to detect the chemo-sensitivity of cells. Absorbance values
were expressed as percentages relative to controls, and the
concentrations resulting in 50% inhibition of cell growth
(IC50 values) were calculated.
Statistical analysis
Results were presented as means of three independent
experiments (± SD). Statistical analyses were performed
using SPSS 13.0. Comparisons of optical density values,
percentage of viable cells and number of apoptotic cells
among groups were performed using the two-tailed Stu-
dent's t test or ANOVA. P < 0.05 was considered statisti-
cally significant.
Results
Knock-down of AEG-1 by specific siRNAs
In order to knock down AEG-1, we used two different 21-
base pair siRNA constructs: AEG-1-siRNA1 and AEG-1-
siRNA2. As shown in Figure 1, transfected M17 and SK-N-
SH with either AEG-1-siRNA1 or AEG-1-siRNA2 resulted
in knock down of AEG-1 at both the transcription and
translation levels in each neuroblastoma cell lines. Con-
trol siRNA transfected cells had no significant impact on
AEG-1  expression levels compared with parental cells.
AEG-1-siRNA1 was used to process the follow investiga-
tion.
AEG-1 knockdown inhibits proliferation and promotes 
apoptosis in neuroblastoma cells
In order to examine the role of AEG-1 on neuroblastoma
cell proliferation, we examined the effect of AEG-1 siRNA
on neuroblastoma cell growth and colonogenic assay. As
shown in Figure 2A and 2B, AEG-1-siRNA1 significantly
decreases cell proliferation by 42.9% in M17 and 49.5%
in SK-N-SH at 72 hours compared to control group,
respectively. Furthermore, colony forming ability was also
affected by transfection with AEG-1 siRNA1 (Figure 2C
and 2D).
We also evaluated apoptotic levels of neuroblastoma cell
lines. As shown in Figure 2E and 2F, the apoptotic cell
fraction was 3.75% and 2.9% in control siRNA-trans-
fected M17 and SK-N-SH cells, respectively. In contrast,
they were 13.2% and 11.8% in AEG-1 siRNA1-transfected
cells.
Knock down of AEG-1 accumulates G0/G1-phase cells
Cell proliferation inhibited by knockdown of AEG-1 was
also shown in other types of mammalian cells [9,10]. To
reveal mechanism involved in proliferation inhibition, we
analyzed cell cycle by using flow cytometry. As shown in
Figure 3, knockdown of AEG-1 resulted in accumulation
in the G0/G1 phase and reduction of S and G2/M phase
cell.
Knock down of AEG-1 sensitize cells to cisplatin and 
doxorubicin
Except to operation, chemotherapy is also important in
treatment of neuroblastoma, especially in neoadjuvant
chemotherapy. Here we tested if knock down AEG-1 could
sensitize neuroblastoma cells to chemotherapeutic agents.
M17 and SK-N-SH were exposed to cisplatin and doxoru-
bicin after transfected with AEG-1-siRNA1 for 48 hours.
Cells' viability was evaluated using a MTT assay. As shown
in Figure 4, cells transfected with AEG-1-siRNA1 were
more sensitive to cisplatin and doxorubicin than control.
The sensitivities of M17 and SK-N-SH to cisplatin were
enhanced by knock down of AEG-1 by 4.3- and 4.5-fold
and to doxorubicin by 1.9- and 2.1-fold, respectively.
Discussion
Neuroblastoma is one of the most frequently occurring
solid tumors in children, especially in the first year of life,
when it accounts for 50% of all tumors. It is the second
most common cause of death in children, only preceded
by accidents [5]. Despite many advances in the past three
decades, neuroblastoma has remained an enigmatic chal-Journal of Experimental & Clinical Cancer Research 2009, 28:19 http://www.jeccr.com/content/28/1/19
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Knock-down of AEG-1 by specific siRNAs Figure 1
Knock-down of AEG-1 by specific siRNAs. Fourty-eight hours after transfection, cells were harvested. (A), AEG-1 mRNA 
levels were quantified by real-time PCR analysis. Data were normalized by using GAPDH as an internal standard. *P < 0.05 vs. 
parental cells. (B, C) AEG-1 protein level was analyzed by western blot. β-actin expression was monitored as the internal stand-
ard. *P < 0.05 vs. parental cells. These experiments were performed in triplicate.Journal of Experimental & Clinical Cancer Research 2009, 28:19 http://www.jeccr.com/content/28/1/19
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AEG-1 knockdown inhibits proliferation and promotes apoptosis in neuroblastoma cells Figure 2
AEG-1 knockdown inhibits proliferation and promotes apoptosis in neuroblastoma cells. (A, B) Cell viability was 
evaluated by MTT assay. The results of cell proliferation assay showed a significant decrease in the number of cells by 42.9% in 
M17 and 49.5% in SK-N-SH in 72 h. (C, D) Compared with that seen in the parental cells, the number of colonies was signifi-
cantly reduced in the AEG-1 siRNA1 transfected group (*P < 0.05 vs. parental cells). Each experiment was performed three 
times in triplicate. (E) The apoptosis rate of AEG-1 siRNA1 transfected cells significantly increased by 9.6% ± 1.7% in M17 and 
9.0% ± 1.4% in SK-N-SH cells (*P < 0.05 vs. parental cells), respectively. (F) Representative results are shown. These experi-
ments were performed in triplicate.Journal of Experimental & Clinical Cancer Research 2009, 28:19 http://www.jeccr.com/content/28/1/19
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Knock down of AEG-1 reduces S and G2/M-phase cells Figure 3
Knock down of AEG-1 reduces S and G2/M-phase cells. (A) In both M17 and SK-N-SH cells 48 hours after AEG-1 
siRNA1 transfection, the population of G0/G1 phase was significantly increased and the population of S phase and G2/M phase 
was obviously decreased (*P < 0.05 vs. parental cells). (B) Representative results are shown. These experiments were per-
formed in triplicate.Journal of Experimental & Clinical Cancer Research 2009, 28:19 http://www.jeccr.com/content/28/1/19
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lenge to clinical and basic scientists. Elucidation of the
exact molecular pathways of neuroblastoma will enable
researchers and clinicians to stratify the disease and adapt
therapy to the risk of relapse or progress. A large body of
basic research into genes and oncogenes has accumulated
up till present.
Increased/decreased expression of the molecular factors,
MYCN, H-ras, and trkA is well known in neuroblastoma
[1-4]. However, the poor prognosis for advanced neurob-
lastoma still reflects in part the lack of knowledge about
the tumor's basic biology.
Aberrant AEG-1 expression has been observed in some
solid tumors including breast, brain and prostate [13,14].
Our earlier data have demonstrated that AEG-1 expression
was increased in human neuroblastoma tissues and cul-
tured cells compared to normal brain tissues. The expres-
sion level of AEG-1 was correlated with the clinical staging
of neuroblastoma. Multivariate analysis suggested that
Knock down of AEG-1 sensitized cells to cisplatin and doxorubicin Figure 4
Knock down of AEG-1 sensitized cells to cisplatin and doxorubicin. M17 and SK-N-SH cells were transfected with 
AEG-1 siRNA1 or control siRNA for 48 h, then exposed to various concentrations of cisplatin or doxorubicin for 48 h, and the 
viability was accessed. The percentage of cell growth was calculated by comparison of the A570 reading from treated cells ver-
sus control cells. The IC50 value of M17 cells to cisplatin (A) and doxorubicin (B) was 6.4 and 3.4 μM, respectively. The IC50 val-
ues of SK-N-SH cells to cisplatin (C) and doxorubicin (D) were 3.3 and 2.8 μM, respectively. These results demonstrated that 
transfection of AEG-1 siRNA1 increased the sensitivity of M17 and SK-N-SH to cisplatin by 4.3- and 4.5-fold and to doxorubicin 
by 1.9- and 2.3-fold, respectively. Each experiment was performed three times in triplicate.Journal of Experimental & Clinical Cancer Research 2009, 28:19 http://www.jeccr.com/content/28/1/19
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AEG-1 might be an independent biomarker for the predic-
tion of prognosis of neuroblastoma (submitted). In our
current study, we evaluated the possibility of AEG-1 as a
therapeutic target of neuroblastoma.
AEG-1  has been reported to be upregulated in several
malignancies and play a critical role in Ha-ras-mediated
oncogenesis through the phosphatidylinositol 3-kinase/
AKT signaling pathway [15]. Emdad et al. documented
that AEG-1  is a significant positive regulator of NF-κB
[11]. Activation of NF-κB by AEG-1 could represent a key
molecular mechanism by which AEG-1 promotes anchor-
age-independent growth and invasion, two central fea-
tures of the neoplastic phenotype. Furthermore, Kikuno et
al. revealed that aberrant AEG-1 expression as a positive
auto-feedback activator of AKT and as a suppressor of
FOXO3a in prostatic cancer cells [10]. In this study, we
adopted a strategy of RNA interference to inhibit expres-
sion of AEG-1 in two neuroblastoma cell lines, M17 and
SK-N-SH. The results revealed that after transfection with
AEG-1 siRNA, mRNA level and protein level of the AEG-1
gene decreased, and meanwhile cell growth inhibited and
apoptosis increased. Therefore, our data also confirmed
that AEG-1 serves in regulating both cell proliferation and
survival. AEG-1 knockdown may not only effect the NF-κB
signaling pathway, but also the PI3K/AKT signaling path-
way, either directly or indirectly and also influences the
function of several PI3K/AKT downstream substrates. Our
reports also shown that knockdown of AEG-1 resulted in
accumulation in the G0/G1 phase and reduction of S and
G2/M phase cell. The eukaryotic cell cycle is regulated via
the sequential activation and inactivation of CDKs that
drive cell cycle progression through the phosphorylation
and dephosphorylation of regulatory proteins. The under-
lying mechanisms are still unclear.
Since AEG-1 might play important role in neuroblastoma
cell growth, we explored the therapeutic role of AEG-1 in
combination with chemotherapeutic drug. We found that
knockdown of AEG-1 synergistically enhanced the cyto-
toxicity of cisplatin and doxorubicin. Cisplatin forms
inter- and intra-strand DNA cross-links. The cytotoxic
effect was likely a result of inhibition of replication by cis-
platin-DNA adducts and induction of apoptosis. Cisplatin
is a widely used anticancer agent and frequently applied
via transarterial chemo-embolization or systemically in
neuroblastoma. Our results suggest that cisplatin chemo-
therapy could be more effective in combination with
RNAi mediated knockdown of AEG-1. Clearly, for the
development of such a therapeutic strategy for clinical
use, a suitable vector system is necessary. These will be fur-
ther explored in future work.
In summary, our present study suggests that overex-
pressed  AEG-1  enhance the tumorogenic properties of
neuroblastoma cells. Knockdown of AEG-1 could inhibit
proliferation and enhance chemo-sensitivity to cisplatin
or doxorubicin in neuroblastoma cells and therefore it
could be a new adjuvant therapy for neuroblastoma.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
HL and LW carried out cell transfection, immunoblotting
analysis; CL and LX contributed to cell transfection, cell
treatments, RT-PCR and flow cytometry analysis. HL, XS
and RS supervised experimental work and wrote the man-
uscript. All authors read and approved the final manu-
script.
References
1. Castleberry RP: Predicting outcome in neuroblastoma.  N Engl
J Med 1999, 340:1992-1993.
2. Castel V, Garcia-Miguel P, Canete A, Melero C, Navajas A, Ruiz-
Jimenez JI, Navarro S, Badal MD: Prospective evaluation of the
International Neuroblastoma Staging System (INSS) and
the International Neuroblastoma Response Criteria (INRC)
in a multicentre setting.  Eur J Cancer 1999, 35:606-611.
3. Castleberry RP, Pritchard J, Ambros P, Berthold F, Brodeur GM, Cas-
tel V, Cohn SL, De Bernardi B, Dicks-Mireaux C, Frappaz D, Haase
GM, Haber M, Jones DR, Joshi VV, Kaneko M, Kemshead JT, Kogner
P, Lee REJ, Matthay KK, Michon JM, Monclair R, Roald BR, Seeger RC,
Shaw PJ, Shimada H, Shuster JJ: The International Neuroblast-
oma Risk Groups (INRG): a preliminary report.  Eur J Cancer
1997, 33:2113-2116.
4. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, Stram
DO, Gerbing RB, Lukens JN, Matthay KK, Castleberry RP: The
International Neuroblastoma Pathology Classification (the
Shimada system).  Cancer 1999, 86:364-372.
5. Chan HS, Gallie BL, DeBoer G, Haddad G, Ikegaki N, Dimitroulakos
J, Yeger H, Ling V: MYCN protein expression as a predictor of
neuroblastoma prognosis.  Clin Cancer Res 1997, 3:1699-1706.
6. Gordon SJ, Pearson AD, Reid MM, Craft AW: Toxicity of single-
day high-dose vincristine, melphalan, etoposide and carbopl-
atin consolidation with autologous bone marrow rescue in
advanced neuroblastoma.  Eur J Cancer 1992, 28A:1319-1323.
7. Su ZZ, Kang DC, Chen Y, Pekarskaya O, Chao W, Volsky DJ, Fisher
PB: Identification and cloning of human astrocyte genes dis-
playing elevated expression after infection with HIV-1 or
exposure to HIV-1 envelope glycoprotein by rapid subtrac-
tion hybridization, RaSH.  Oncogene 2002, 21:3592-3602.
8. Kang DC, Su ZZ, Sarkar D, Emdad L, Volsky DJ, Fisher PB: Cloning
and characterization of HIV-1-inducible astrocyte elevated
gene-1, AEG-1.  Gene 2005, 353:8-15.
9. Lee SG, Su ZZ, Emdad L, Sarkar D, Fisher PB: Astrocyte elevated
gene-1 (AEG-1) is a target gene of oncogenic Ha-ras requir-
ing phosphatidylinositol 3-kinase and c-Myc.  Proc Natl Acad Sci
USA 2006, 103:17390-17395.
10. Kikuno N, Shiina H, Urakami S, Kawamoto K, Hirata H, Tanaka Y,
Place RF, Pookot D, Majid S, Igawa M, Dahiya R: Knockdown of
astrocyte-elevated gene-1 inhibits prostate cancer progres-
sion through upregulation of FOXO3a activity.  Oncogene
2007, 26:7647-7655.
11. Emdad L, Sarkar D, Su ZZ, Randolph A, Boukerche H, Valerie K,
Fisher PB: Activation of the nuclear factor kappaB pathway by
astrocyte elevated gene-1: implications for tumor progres-
sion and metastasis.  Cancer Res 2006, 66:1509-1516.
12. Song X, Liu X, Chi W, Liu Y, Wei L, Wang X, Yu J: Hypoxia-induced
resistance to cisplatin and doxorubicin in non-small cell lung
cancer is inhibited by silencing of HIF-1alpha gene.  Cancer
Chemother Pharmacol 2006, 58:776-784.
13. Brown DM, Ruoslahti E: Metadherin, a cell surface protein in
breast tumors that mediates lung metastasis.  Cancer Cell 2004,
5:365-374.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Experimental & Clinical Cancer Research 2009, 28:19 http://www.jeccr.com/content/28/1/19
Page 9 of 9
(page number not for citation purposes)
14. Li J, Zhang N, Song LB, Liao WT, Jiang LL, Gong LY, Wu J, Yuan J,
Zhang HZ, Zeng MS, Li M: Astrocyte elevated gene-1 is a novel
prognostic marker for breast cancer progression and overall
patient survival.  Clin Cancer Res 2008, 14:3319-3326.
15. Lee SG, Su ZZ, Emdad L, Sarkar D, Franke TF, Fisher PB: Astrocyte
elevated gene-1 activates cell survival pathways through
PI3K-Akt signaling.  Oncogene 2008, 27:1114-1121.